Bristol-Myers Squibb
BMY
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • 1 day ago • BMY
10 Sector Evaluation High Yield 4.5%+ Winners To Buy
CNBC • 2 days ago • BMY
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
Seeking Alpha • 2 days ago • BMY
Bristol-Myers Squibb Company (BMY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Business Wire • 3 days ago • BMY
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
Zacks Investment Research • 10 days ago • BMY
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.